Grufity logoGrufity logo

Teva Pharmaceutical Industries Ltd Stock Research

TEVA

8.81USD+0.08(+0.92%)Market Closedas of 23 Mar 2023, 09:54 am

Market Summary

USD8.81+0.08
Market Closedas of 23 Mar 2023, 09:54 am
0.92%

TEVA Alerts

TEVA Stock Price

TEVA RSI Chart

TEVA Valuation

Market Cap

9.4B

Price/Earnings (Trailing)

-4.01

Price/Sales (Trailing)

0.63

EV/EBITDA

-8.21

Price/Free Cashflow

9.06

TEVA Price/Sales (Trailing)

TEVA Profitability

EBT Margin

-20.54%

Return on Equity

-29.8%

Return on Assets

-5.35%

Free Cashflow Yield

11.03%

TEVA Fundamentals

TEVA Revenue

Revenue (TTM)

14.9B

Revenue Y/Y

-5.27%

Revenue Q/Q

8.04%

TEVA Earnings

Earnings (TTM)

-2.4B

Earnings Y/Y

-667.92%

Earnings Q/Q

-2.3K%

Price Action

52 Week Range

6.7811.45
(Low)(High)

Last 7 days

-10.2%

Last 30 days

-15.8%

Last 90 days

-3.2%

Trailing 12 Months

15.6%

TEVA Financial Health

Current Ratio

1.05

TEVA Investor Care

Shares Dilution (1Y)

0.73%

Diluted EPS (TTM)

-2.12

Peers (Alternatives to Teva Pharmaceutical Industries)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
404.8B
94.9B
-5.16% -10.64%
22.56
4.26
1.25% -14.07%
296.8B
28.5B
-5.67% 20.74%
47.53
10.4
0.79% 11.88%
272.8B
59.3B
-1.75% 40.02%
17.88
4.63
21.72% 11.27%
226.4B
100.3B
-8.43% -20.95%
7.22
2.26
23.43% 42.74%
142.7B
46.2B
-7.78% -1.12%
22.55
3.09
-0.49% -9.54%
MID-CAP
4.8B
4.5B
-0.20% -5.41%
-34.17
1.08
7.56% -104.06%
3.3B
2.2M
105.10% 171.03%
-10.52
1.5K
-80.71% -4.88%
SMALL-CAP
1.9B
667.2M
-9.96% 17.66%
31.57
2.87
15.09% 13.64%
1.6B
602.5M
-17.77% -52.80%
-2.74
2.63
18.18% -18.59%
991.7M
478.9M
-11.35% -65.42%
-0.32
2.07
-31.50% -634.70%
792.9M
285.2M
-7.22% -37.95%
3.6
2.78
-27.21% -40.28%
768.8M
114.5M
-15.28% -37.42%
-4.56
6.72
27.90% 57.40%
541.5M
29.8M
-40.95% -47.43%
-6.23
18.2
340.05% 4.35%
400.7M
51.5M
-2.49% -0.39%
-5.64
7.78
18.32% -984.05%
94.1M
2.3B
-43.99% -88.43%
-0.03
0.04
-22.53% -376.66%

Financials for Teva Pharmaceutical Industries

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue-1.4%14,925,000,00015,142,000,00015,434,000,00015,558,000,00015,878,000,000
Gross Profit-3.9%6,973,000,0007,253,000,0007,378,000,0007,457,000,0007,594,000,000
  S&GA Expenses-3.5%2,265,000,0002,348,000,0002,406,000,0002,427,000,0002,429,000,000
EBITDA-36.2%-809,000,000-594,000,0001,712,000,0002,879,000,000-
EBITDA Margin-40.8%-0.05-0.040.110.18-
Earnings Before Taxes-43.2%-3,065,000,000-2,140,000,000-1,924,000,000-456,000,000658,000,000
EBT Margin-45.3%-0.21-0.14-0.12-0.030.04
Interest Expenses3.8%948,000,000913,000,000---
Net Income-82.4%-2,353,000,000-1,290,000,000-1,054,000,000-615,000,000417,000,000
Net Income Margin-85.1%-0.16-0.09-0.07-0.040.03
Free Cahsflow102.7%1,042,000,000514,000,000476,000,000585,000,000236,000,000
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets-0.6%44,00644,25245,93247,05947,666
  Current Assets5.2%12,05111,45312,16412,45112,573
    Cash Equivalents25.9%2,8012,2252,0582,1752,165
  Inventory-0.7%3,8333,8594,0494,0123,818
  Net PPE3.1%5,7395,5685,7405,9325,982
  Goodwill-4.3%17,63318,43318,83719,98620,040
Liabilities1.7%35,31534,73436,10336,79936,422
  Current Liabilities-0.6%11,46911,53410,99611,61311,027
    LT Debt, Current-17.4%1,6962,0541,403--
Shareholder's Equity-9.9%7,8978,7679,82810,26010,278
  Retained Earnings-10.5%-12,882-11,660-11,716-11,484-10,529
  Additional Paid-In Capital0.1%27,68827,65227,62527,58727,561
Accumulated Depreciation-5,241----
Shares Outstanding0.1%1,1111,1101,107--
Minority Interest5.7%794751791916966
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations48.2%1,5901,0731,0591,154798
  Share Based Compensation2.5%124121122112119
Cashflow From Investing-10.6%6567348751,1761,523
Cashflow From Financing-16.4%-1,487-1,277-2,014-1,677-2,172

Risks for TEVA

What is the probability of a big loss on TEVA?

100%


Probability that Teva Pharmaceutical Industries stock will be more than 20% underwater in next one year

91.9%


Probability that Teva Pharmaceutical Industries stock will be more than 30% underwater in next one year.

43.9%


Probability that Teva Pharmaceutical Industries stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does TEVA drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Teva Pharmaceutical Industries was unfortunately bought at previous high price.

Drawdowns

Returns for TEVA

Cumulative Returns on TEVA

-13.2%


10-Year Cumulative Returns

-22.7%


7-Year Cumulative Returns

-13.9%


5-Year Cumulative Returns

1.1%


3-Year Cumulative Returns

What are the long-term rolling returns for TEVA?

FIve years rolling returns for Teva Pharmaceutical Industries.

Annualized Returns

Which funds bought or sold TEVA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-71.97
-968,740
449,260
-%
2023-03-06
Rockefeller Capital Management L.P.
added
16.82
36,000
148,000
-%
2023-02-28
Voya Investment Management LLC
reduced
-6.3
76,553
1,384,550
-%
2023-02-27
Parallax Volatility Advisers, L.P.
reduced
-18.26
-735,056
8,905,940
0.01%
2023-02-24
NATIXIS
new
-
60,785
60,785
-%
2023-02-24
National Pension Service
unchanged
-
2,818
19,772
-%
2023-02-21
MACQUARIE GROUP LTD
added
17.69
97,437
393,437
-%
2023-02-21
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
reduced
-0.73
17,719
166,719
-%
2023-02-21
DGS Capital Management, LLC
added
39.61
50,932
139,089
0.09%
2023-02-17
TRUIST FINANCIAL CORP
reduced
-5.16
92,358
1,378,360
-%

1–10 of 43

Latest Funds Activity

Are funds buying TEVA calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own TEVA
No. of Funds

Teva Pharmaceutical Industries News

Digital Journal

Global Small Molecule Drug Discovery Market 2022 – 2030 ....

Digital Journal,
12 minutes ago

Digital Journal

Digital Journal

Schedule 13G FIlings of Teva Pharmaceutical Industries

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2023
capital research global investors
10.3%
114,793,989
SC 13G/A
Feb 11, 2022
capital research global investors
12.0%
132,350,750
SC 13G/A
Feb 16, 2021
capital research global investors
11.9%
130,140,247
SC 13G/A
Feb 03, 2021
wellington management group llp
0.03%
310,793
SC 13G/A
Feb 14, 2020
capital research global investors
11.9%
130,950,677
SC 13G/A
Feb 05, 2020
franklin resources inc
1.8%
19,916,016
SC 13G/A
Jan 28, 2020
wellington management group llp
7.43%
81,123,996
SC 13G

TEVA Fair Value

Teva Pharmaceutical Industries fair value in different scenarios

The table shows the Fair Value estimates for Teva Pharmaceutical Industries for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

-

-

-

-

-

-

-

-

-

-
Current Inflation

5.96

-32.35%

6.83

-22.47%

9.92

12.60%

12.06

36.89%

13.99

58.80%
Very High Inflation

-

-

-

-

-

-

-

-

-

-

Historical Teva Pharmaceutical Industries Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Teva Pharmaceutical Industries

View All Filings
Date Filed Form Type Document
Mar 09, 2023
8-K
Current Report
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 08, 2023
4
Insider Trading
Mar 07, 2023
4
Insider Trading
Mar 07, 2023
4
Insider Trading
Mar 07, 2023
4
Insider Trading
Mar 07, 2023
4
Insider Trading
Mar 07, 2023
4
Insider Trading

Latest Insider Trading transactions for TEVA

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-07
Dethlefs Sven
sold
-547,440
9.4279
-58,066
evp, north america commercial
2023-03-07
Stark David Matthew
sold
-466,445
9.4279
-49,475
exec. vp chief legal officer
2023-03-07
Drape Eric
sold
-44,301
9.4279
-4,699
executive vp global operations
2023-03-07
Daniell Richard
sold
-509,173
9.4279
-54,007
exec. vp, european commercial
2023-03-06
Drape Eric
sold
-15,551
9.9309
-1,566
executive vp global operations
2023-03-06
Dethlefs Sven
sold
-192,213
9.9309
-19,355
evp, north america commercial
2023-03-06
Daniell Richard
sold
-178,776
9.9309
-18,002
exec. vp, european commercial
2023-03-06
Stark David Matthew
sold
-163,770
9.9309
-16,491
exec. vp chief legal officer
2023-03-05
Dethlefs Sven
acquired
-
-
24,952
evp, north america commercial
2023-03-05
Daniell Richard
acquired
-
-
22,576
exec. vp, european commercial

1–10 of 50

KÃ¥re Schultz
37500
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

TEVA Income Statement

2022-09-30
Consolidated Statements of Income (Loss) - USD ($)
shares in Millions, $ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Net revenues$ 3,595$ 3,887$ 11,041$ 11,778
Cost of sales1,9262,0935,8396,234
Gross profit1,6691,7945,2035,544
Research and development expenses175222628723
Selling and marketing expenses5395971,7161,798
General and administrative expenses283291892822
Intangible assets impairments2421223295
Goodwill impairment007450
Other assets impairments, restructuring and other items3662282227
Legal settlements and loss contingencies19532,048113
Other income(2)(25)(88)(73)
Operating income (loss)419623(1,244)1,638
Financial expenses, net252241721805
Income (loss) before income taxes166382(1,964)833
Income taxes (benefit)10776(792)235
Share in (profits) losses of associated companies, net15(20)(9)
Net income (loss)58302(1,152)608
Net income (loss) attributable to non-controlling interests311(21)32
Net income (loss) attributable to Teva$ 56$ 292$ (1,132)$ 576
Earnings (loss) per share attributable to ordinary shareholders:    
Basic$ 0.05$ 0.26$ (1.02)$ 0.52
Diluted$ 0.05$ 0.26$ (1.02)$ 0.52
Weighted average number of shares (in millions):    
Basic1,1111,1031,1091,102
Diluted1,1191,1091,1091,109

TEVA Balance Sheet

2022-09-30
Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 2,225$ 2,165
Accounts receivables, net of allowance for credit losses of $94 million and $90 million as of September 30, 2022 and December 31, 20213,7304,529
Inventories3,8593,818
Prepaid expenses1,0451,075
Other current assets579965
Assets held for sale1619
Total current assets11,45312,573
Deferred income taxes1,546596
Other non-current assets438515
Property, plant and equipment, net5,5685,982
Operating lease right-of-use assets422495
Identifiable intangible assets, net6,3937,466
Goodwill[1]18,43320,040
Total assets44,25247,666
Current liabilities:  
Short-term debt2,7691,426
Sales reserves and allowances3,6484,241
Accounts payables1,6351,686
Employee-related obligations496563
Accrued expenses2,0412,208
Other current liabilities945903
Total current liabilities11,53411,027
Long-term liabilities:  
Deferred income taxes503784
Other taxes and long-term liabilities3,8462,578
Senior notes and loans18,49721,617
Operating lease liabilities354416
Total long-term liabilities23,20025,395
Commitments and contingencies, see note 10
Total liabilities34,73436,422
Teva shareholders' equity:  
Ordinary shares of NIS 0.10 par value per share; September 30, 2022 and December 31, 2021: authorized 2,495 million shares; issued 1,216 million shares and 1,209 million shares, respectively.5757
Additional paid-in capital27,65227,561
Accumulated deficit(11,660)(10,529)
Accumulated other comprehensive loss(3,153)(2,683)
Treasury shares as of September 30, 2022 and December 31, 2021: 106 million ordinary shares(4,128)(4,128)
Stockholders' equity attributable to Teva shareholders8,76710,278
Non-controlling interests751966
Total equity9,51911,244
Total liabilities and equity$ 44,252$ 47,666
[1]Accumulated goodwill impairment as of September 30, 2022 and December 31, 2021 was approximately $26.3 billion and $25.6 billion, respectively.